| 58 | 0 | 21 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：通过检测川崎病(Kawasaki disease, KD)患儿血清中氧化型低密度脂蛋白(oxidized low-density lipoprotein, ox-LDL)及前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9, PCSK9)的表达水平，探究两者在KD中的变化及其临床意义。方法：选取苏州大学附属儿童医院2023年4—8月收治住院的KD患儿151例为KD组，并选择同期行疝气修补手术无感染状态患儿48例为健康对照(healthy control, HC)组，呼吸道感染伴发热患儿48例为发热对照(febrile control, FC)组。按照超声心动图结果，将KD组患儿分为冠状动脉损伤(coronary artery lesion, CAL)组及无冠状动脉损伤(non-coronary artery lesion, NCAL)组。采用ELISA测定各组血清中ox-LDL和PCSK9的表达水平，并收集其相关临床实验室指标。结果：(1)KD组患儿血清ox-LDL及PCSK9水平均高于FC组和HC组(均P<0.05)。(2)CAL组患儿急性期血清ox-LDL、PCSK9水平高于NCAL组(P<0.05)。(3)经静脉注射免疫球蛋白(intravenous immunoglobulin,IVIG)治疗后的KD患儿血清ox-LDL、PCSK9水平较治疗前明显下降(P<0.05)，且低于FC组(P<0.05)，与HC组比较差异无统计学意义(P>0.05)。结论：KD急性期患儿血清ox-LDL、PCSK9水平升高，且急性期CAL患儿ox-LDL、PCSK9水平高于NCAL患儿，表明ox-LDL及PCSK9与川崎病的发病及CAL的形成相关。
Abstract：Objective: To investigate the changes and clinical significance of oxidized low-density lipoprotein(ox-LDL) and proprotein convertase subtilisin/kexin type 9(PCSK9) in Kawasaki disease(KD) by detecting their serum expression levels in children with KD. Methods: A total of 151 KD children hospitalized at the Children,s Hospital Affiliated to Soochow University from April to August 2023 were enrolled as the KD group. Additionally, 48 children undergoing hernia repair surgery without infection healthy control(HC) group and 48 children with respiratory infections febrile control(FC) group were included as controls. Based on echocardiography results, KD patients were further divided into coronary artery lesion(CAL) group and noncoronary artery lesion(NCAL) group. The expression of ox-LDL and PCSK9 in the serum of each group were measured by ELISA,and the relevant clinical laboratory indicators were collected. Results:(1)Serum ox-LDL and PCSK9 levels in the KD group were significantly higher than those in the FC group and HC group(all P<0.05).(2)The serum levels of ox-LDL and PCSK9 in the CAL group of children during the acute phase were higher than those in the NCAL group(P<0.05).(3)The serum levels of oxLDL and PCSK9 in KD children with intravenous immunoglobulin(IVIG) treatment were significantly lower than those before treatment(P<0.05), which were not statistically significant compared with those in the FC group and HC group(P>0.05). Conclusions:Serum ox-LDL and PCSK9 levels are elevated in KD children during the acute phase, with higher levels observed in the CAL children than in the NCAL children. Indicating that ox-LDL and PCSK9 are associated with the onset of KD and the formation of CAL.
[1]Dillon M J, Eleftheriou D, Brogan P A. Medium-size-vessel vasculitis[J]. Pediatr Nephrol, 2010, 25(9):1641-1652.
[2]Sundel R P. Kawasaki disease[J]. Rheum Dis Clin N Am,2015, 41(1):63-73.
[3]泮思林,刘芳,罗刚.日本《川崎病诊断指南第6次修订版》要点解读[J].中国实用儿科杂志, 2020, 35(11):846-849.
[4]Nomura O, Fukuda S, Ota E, et al. Monoclonal antibody and anti-cytokine biologics for Kawasaki disease:a systematic review and meta-analysis[J]. Semin Arthritis Rheum,2021, 51(5):1045-1056.
[5]Youn Y, Kim J, Hong Y M, et al. Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin[J]. Pediatr Infect Dis J,2016, 35(4):457-459.
[6]Singh S, Bhattad S, Gupta A, et al. Mortality in children with Kawasaki disease:20 years of experience from a tertiary care centre in North India[J]. Clin Exp Rheumatol, 2016,34(3 Suppl 97):S129-S133.
[7]周光中,杜荣增,廖德宁. γ-干扰素诱导蛋白10及载脂蛋白A1、B在川崎病早期诊断中的意义[J].广东医学, 2015,36(24):3794-3797.
[8]顾晓琼,徐家瑜,张小玲,等.川崎病儿童载脂蛋白和脂蛋白及血脂水平变化的临床研究[J].中国儿童保健杂志,2004, 12(3):219-222.
[9]张惠,张晓斌,陈俊义.川崎病患儿急性期血脂水平与冠脉病变关系的研究[J].中国卫生标准管理, 2023, 14(24):23-27.
[10]Ji K T, Qian L, Nan J L, et al. Ox-LDL induces dysfunction of endothelial progenitor cells via activation of NF-κB[J]. Biomed Res Int, 2015, 2015:175291.
[11]Sekine K, Mochizuki H, Inoue Y, et al. Regulation of oxidative stress in patients with Kawasaki disease[J]. Inflammation, 2012, 35(3):952-958.
[12]Leander K, Mälarstig A, Van’t Hooft F M, et al. Circulating proprotein convertase subtilisin/kexin type 9(PCSK9)predicts future risk of cardiovascular events independently of established risk factors[J]. Circulation, 2016, 133(13):1230-1239.
[13]Gai M T, Adi D, Chen X C, et al. Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors[J]. Sci Rep, 2021, 11(1):11450.
[14]Huang L X, Li Y J, Cheng Z, et al. PCSK9 promotes endothelial dysfunction during sepsis via the TLR4/MyD88/NF-κB and NLRP3 pathways[J]. Inflammation, 2023, 46(1):115-128.
[15]Mccrindle B W, Rowley A H, Newburger J W, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a scientific statement for health professionals from the American heart association[J]. Circulation, 2017, 135(17):e927-e999.
[16]中华医学会儿科学分会心血管学组,中华儿科杂志编辑委员会.川崎病冠状动脉病变的临床处理建议(2020年修订版)[J].中华儿科杂志, 2020, 58(9):718-724.
[17]Ae R, Makino N, Kosami K, et al. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease:the nationwide survey in Japan, 2017-2018[J]. J Pediatr, 2020, 225:23-29.e2.
[18]Shulman S T, Rowley A H. Kawasaki disease:insights into pathogenesis and approaches to treatment[J]. Nat Rev Rheumatol, 2015, 11(8):475-482.
[19]Duan C, Du Z D, Wang Y, et al. Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease[J]. World J Pediatr, 2014, 10(3):232-237.
[20]陈娟,王志文,魏宇淼.特异性抗体P210减轻Ox-LDL诱导的血管内皮细胞损伤[J].华中科技大学学报(医学版), 2021, 50(1):1-6.
[21]Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque:role of activated macrophages and inflammatory cytokines[J]. Circulation, 2002, 106(24):3024-3030.
[22]He Y E, Qiu H X, Wu R Z, et al. Oxidised low-density lipoprotein and its receptor-mediated endothelial dysfunction are associated with coronary artery lesions in Kawasaki disease[J]. J Cardiovasc Transl Res, 2020, 13(2):204-214.
[23]Kattoor A J, Kanuri S H, Mehta J L. Role of ox-LDL and LOX-1 in atherogenesis[J]. Curr Med Chem, 2019, 26(9):1693-1700.
[24]刘磊,叶梓,刘学波.冠状动脉瘤样扩张的研究进展[J].中国心血管杂志, 2022, 27(3):292-295.
[25]Zhao T R, Jiang Q S, Li W M, et al. Antigen-presenting cell-like neutrophils foster T cell response in hyperlipidemic patients and atherosclerotic mice[J]. Front Immunol,2022, 13:851713.
[26]Diehl P, Nienaber F, Zaldivia M T K, et al. Lysophosphatidylcholine is a major component of platelet microvesicles promoting platelet activation and reporting atherosclerotic plaque instability[J]. Thromb Haemost, 2019, 119(8):1295-1310.
[27]Rossaint J, Margraf A, Zarbosk A. Role of platelets in leukocyte recruitment and resolution of inflammation[J]. Front Immunol, 2018, 9:2712.
[28]沈西伟,赵建美.川崎病相关的神经系统损害的研究进展[J].南通大学学报(医学版), 2023, 43(2):170-173.
[29]Cariou B, May C L, Costet P. Clinical aspects of PCSK9[J].Atherosclerosis, 2011, 216(2):258-265.
[30]李风梅,刘忠民.人前蛋白转化酶枯草溶菌素9基因的研究进展[J].临床检验杂志, 2014, 32(3):219-221.
[31]Momtazi-Borojeni A A, Sabouri-Rad S, Gotto A M, et al.PCSK9 and inflammation:a review of experimenta l and clinical evidence[J]. Eur Heart J Cardiovasc Pharmacother,2019, 5(4):237-245.
[32]Punch E, Klein J, Diaba-Nuhoho P, et al. Effects of PCSK9targeting:alleviating oxidation, inflammation, and atherosclerosis[J]. J Am Heart Assoc, 2022, 11(3):e023328.
[33]Tang Y, Li S L, Hu J H, et al. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes[J]. Cardiovasc Diabetol, 2020, 19(1):33.
[34]Qi Z Y, Hu L, Zhang J J, et al. PCSK9(proprotein convertase subtilisin/kexin 9)enhances platelet activation, thrombosis, and myocardial infarct expan sion by binding to platelet CD36[J]. Circulation, 2021, 143(1):45-61.
[35]Akhmedov A, Sawamura T, Chen C H, et al. Lectin-like oxidized low-density lipoprotein receptor-1(LOX-1):a crucial driver of atherosclerotic cardiovascular disease[J]. Eur Heart J, 2021, 42(18):1797-1807.
[36]Ding Z F, Liu S J, Wang X W, et al. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages[J]. Cardiovasc Res, 2018, 114(8):1145-1153.
[37]任懿,尹伶. γ-谷氨酰转移酶与心血管疾病相关性的研究进展[J].实用心脑肺血管病杂志, 2020, 28(5):107-111.
[38]刘春霞. γ-谷氨酰基转移酶与早发冠心病及其冠脉病变严重程度的相关性分析[D].沈阳:沈阳医学院, 2022.
[39]Asano K, Kubo M, Yonemoto K, et al. Im pact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study:the Hisayama study[J].Int J Cancer, 2008, 122(4):909-914.
[40]Sun Y, Liu L H, Yang R H. PTX3 promotes IVIG res istance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway[J]. Open Life Sci, 2023, 18(1):20220735.
基本信息:
DOI：10.16424/j.cnki.cn32-1807/r.2026.02.004
中图分类号:R725.4
引用信息:
[1]黄鑫,王红旭,王佳丽,等.血清ox-LDL、PCSK9在川崎病中的表达及临床价值研究[J].南通大学学报(医学版),2026,46(02):122-126.DOI:10.16424/j.cnki.cn32-1807/r.2026.02.004.
基金信息:
国家自然科学基金面上项目(82472207); 江苏省科技计划项目(BE2023714); 姑苏卫生人才项目(GSWS2019015); 苏州市科技发展项目(SKY2023058,SKJY2021108)
2025-11-20
2025-11-20
2025-11-20